Biogen Inc. (BIIB) Earnings Call Transcript & Summary

July 20, 2022

NASDAQ US Health Care Biotechnology earnings 64 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Hello, and thanks for joining us on Biogen's call covering the second quarter of 2022. To get us started, I'd ask that all of you visit the Investors area of biogen.com, where you'll be able to locate both the earnings release and the accompanying financial tables — these contain our GAAP financial measures as well as a reconciliation between the GAAP and non-GAAP financial measures we'll be talking about today. Tables 1 and 2 contain our GAAP financials, while a reconciliation of our GAAP results to non-GAAP financial results appears in Table 4. It's our view that non-GAAP financial results give a better picture of the business's ongoing economics and show the way we run things internally. Slides are also up on our website, and they track the topics being discussed on this call. I want to note that forward-looking statements will be made, and those rest on what we currently expect and believe. Such statements carry certain risks and uncertainties, and what actually happens could be materially different. For more specifics, please review the risk factors covered in our SEC filings. With me on today's call are our Chief Executive Officer, Michel Vounatsos; Dr. Priya Singhal, Interim Head of Research and Development; and our CFO, Mike McDonnell. <<operator_script>> Michel, over to you.

Michel Vounatsos

executive
#2

Hello to all of you, and I appreciate you being here with us today. During Q2, Biogen kept up strong execution, and it's a pleasure to announce that we're lifting the financial guidance we'd provided for the entire year. In our view, the major accomplishments from this quarter represent essential milestones as we work toward generating fresh value over the long run for patients as well as shareholders. To start, alongside Eisai, we've received priority review for lecanemab through the accelerated approval route in the United States, targeting early Alzheimer's disease; a decision from the FDA is anticipated by January 6 of the coming year; and at the same time, we're eagerly awaiting the Phase III results that should arrive in the fall. In addition, working with Sage, we shared favorable results concerning postpartum depression. The SKYLARK study has become the second favorable Phase III trial backing zuranolone's potential in PPD, alongside four other favorable randomized controlled trials in major depressive disorders; in our view, a considerable amount of evidence points to a meaningful opportunity for zuranolone. Chasing innovation, though, inevitably brings disappointments, and we felt let down upon finding out that the Phase II trial of BIIB104 in schizophrenia did not yield positive results. Now I'll turn to the short-term operational goals we laid out during our previous call, while Priya will go over our latest R&D advances, and Mike will cover how we performed in the second quarter. To begin, we're maintaining our practice of directing R&D funding toward initiatives showing the most promise, while simultaneously working to rebalance risk across the pipeline as a whole. As an illustration, we plan to speed up the regulatory submission for zuranolone in postpartum depression after the favorable SKYLARK study; beyond that, we've shut down certain R&D initiatives where we see diminished odds of success, including BIIB076, an anti-tau antibody for Alzheimer's disease; and BIIB100, a small molecule XPO1 inhibitor for ALS. Next, we're still on schedule to carry out the cost-cutting and productivity steps we described during our prior call, so that our expenses better match our revenue base, all while keeping our attention fixed on execution. Third, we're chasing further worldwide growth possibilities, concentrating on important emerging markets; that covers China, where the SPINRAZA launch has given us reason for optimism. Fourth, our attention is on generating fresh momentum within our biosimilars operation. We very recently introduced BYOOVIZ, the first biosimilar that references LUCENTIS, in the United States, marking Biogen's inaugural move into the American biosimilars sector. We likewise anticipate kicking off BYOOVIZ launches beyond the United States early in the coming year. Having wrapped up the sale of our joint venture stake in Samsung Bioepis during the second quarter, we've gained greater capacity to grow the biosimilars operation independently, since our goal is to deliver additional biosimilar offerings to a larger patient population across more regions. We keep moving our biosimilars pipeline forward, which encompasses two Phase III programs referencing Eylea and ACTEMRA. Fifth, our attention stayed on capital allocation throughout the quarter. During the quarter, we formed fresh partnerships—one with MedRhythms focused on MS, another with Alectos targeting Parkinson's disease—while we keep assessing opportunities for value creation, whether from within or from outside. Through share buybacks, we gave back roughly $500 million to our shareholders in that same quarter. Progress in our work with Genentech on mosunetuzumab also makes us happy—this CD20/CD3 bispecific antibody recently won approval in the EU for relapsed or refractory follicular lymphoma patients. For that same indication, mosunetuzumab's BLA just received priority review from the FDA, and we anticipate a possible U.S. approval. Combined with recent R&D advances, our momentum in these areas could help fuel growth as time goes on. Naturally, we recognize that some of our programs won't produce the outcomes we want, so we keep pushing forward and constructing a pipeline that is diversified and suitably balanced, aiming to establish and maintain a multi-franchise portfolio in the long run. That covers near-term chances in Alzheimer's disease and depression, then later areas like Parkinson's disease, lupus and stroke across the mid- to late 2020s. We stay dedicated to leveraging every company strength: our people, our commercial portfolio, our manufacturing abilities, our pipeline—which holds 10 programs either in Phase III or filed—and our robust balance sheet, all to produce results for the patients we serve and for our shareholders. I'll hand the call now to Priya for a report on our latest R&D progress.

Priya Singhal

executive
#3

Thanks, Michel, and hello everyone. First off, I want to express appreciation to the whole Biogen team for their commitment and hard work while we kept moving forward a strong, varied R&D pipeline. Like Michel said, this last quarter brought a number of thrilling R&D milestones that, in my view, represent important progress in our effort to bring meaningful new treatments to patients. Let's begin with Alzheimer's disease. Michel noted that the FDA has accepted and given priority review to the BLA for lecanemab in early Alzheimer's disease through the accelerated approval route. Eisai is likewise pushing ahead with the lecanemab Phase III Clarity study, and we expect data this fall. Clarity AD was built to expand on what the earlier Phase II study showed, and it relies on clinically validated measures created to assess multiple dimensions of cognition and function. Because the trial design is so strong, we think the full picture from Clarity AD ought to let us better grasp how clearing amyloid affects different clinical areas of Alzheimer's disease. The FDA has concurred that once finished, Clarity AD may act as a confirmatory study to verify lecanemab's clinical benefit. Should the Clarity AD findings support it, Eisai intends to seek traditional approval for lecanemab in the U.S., EU and Japan by the close of Q1 2023. That schedule might permit lecanemab, if cleared, to be the first anti-amyloid antibody for Alzheimer's disease holding traditional approval. During the prior quarter, Eisai also put out an analysis using simulation modeling drawn from the lecanemab Phase II data, estimating possible long-term health outcomes from lecanemab treatment. According to that analysis, versus standard of care by itself, people given lecanemab alongside standard of care might see slower progression from baseline to mild, moderate and severe Alzheimer's disease by an average of 2.51, 3.13 and 2.34 years, respectively; these early findings might translate into extra quality-adjusted life years plus lower formal and informal costs tied to this disease. Past lecanemab, we keep advancing a pipeline that spans many molecular targets and modalities. That includes BIIB080, our ASO aimed at tau, for which we anticipate launching a Phase II study later this year. Turning to neuropsychiatry. Alongside Sage, we were delighted to report positive findings from the SKYLARK Phase III trial of zuranolone in postpartum depression. SKYLARK hit its primary endpoint and every key secondary endpoint using a 2-week regimen of 50 milligrams zuranolone, showing a statistically significant lessening of depressive symptoms at day 15 versus placebo, the primary endpoint, and at day 3, day 28 and 45. This marks the second positive Phase III trial of zuranolone in postpartum depression and further strengthens the clinical profile of zuranolone seen so far. Postpartum depression ranks among the most frequent medical complications that arise while pregnant or following childbirth. It impacts roughly 1 in 8 mothers — about 500,000 women across the United States annually. Among the typical indicators tied to PPD are depression, sadness, anxiety, thoughts of harming oneself or one's infant, and suicidal thoughts. This represents an area of considerable unmet need, one where fresh treatment choices are urgently required. Now that we have the SKYLARK study results, we are collaborating with Sage to move forward a single regulatory filing for zuranolone in MDD and PPD within the U.S., and we anticipate finishing that in the second half of this year. During the prior quarter, Sage additionally shared findings from the zuranolone human abuse liability potential study at the College on Problems of Drug Dependence Annual Meeting. Findings from that study revealed that 30 and 60 milligrams of zuranolone showed lower abuse potential when compared with alprazolam 1.5 milligrams and 3 milligrams among recreational users of CNS depressants. For 90 milligrams of zuranolone, results were comparable to alprazolam 1.5 milligrams and 3 milligrams. As a reminder, doses of zuranolone examined in the MDD and PPD trials ranged from 20 to 50 milligrams; additionally within neuropsychiatry, we were disappointed to find that the TALLY Phase II study of BIIB104 for cognitive impairment associated with schizophrenia, or CIAS, failed to meet its primary or secondary efficacy endpoints. The majority of adverse events in the BIIB104 treatment arms were mild to moderate in severity. Because of the consistent absence of efficacy seen across primary and secondary measures of cognition and functioning, even though expected drug exposure levels were demonstrated throughout the entire 12-week evaluation period, we have chosen to halt the BIIB104 program in CIAS. We are still analyzing the data and intend to share detailed results at a forthcoming scientific forum. Turning to our neuromuscular portfolio. Last month, we presented new 12-month data from the VALOR Phase III study along with its open-label extension of tofersen in SOD1-ALS, a progressive and rare genetic form of ALS. This analysis was intended to assess participants who began tofersen during the 6-month placebo-controlled period in VALOR, against individuals originally on placebo, who had a delayed start of tofersen treatment during the study's open-label extension. Findings from the new 12-month analysis demonstrated that initial — earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life. In addition, tofersen produced robust and sustained reductions in neurofilament, a marker of axonal injury and neurodegeneration; we believe these results build upon the encouraging trends of reduced disease progression first observed in the VALOR 6-month randomized study and further support the potential for tofersen to slow disease progression in SOD1-ALS; we continue to engage global regulators with these data, and we will provide updates when appropriate. In movement disorders, we initiated the Phase IIb LUMA study in Parkinson's disease for BIIB122, a small molecule LRRK2 inhibitor that we are developing in collaboration with Denali Therapeutics. Mutations in LRRK2 cause the kinase to become hyperactive, and they're thought to be responsible for about 5% of familial cases of Parkinson's disease and 2% of sporadic cases. BIIB122 works by blocking LRRK2, which means it's aimed at a biological pathway that underlies Parkinson's disease — namely, lysosomal function. That's why we think BIIB122 could have therapeutic potential across Parkinson's disease more broadly, in patients who carry pathogenic LRRK2 mutations as well as those who don't. The LUMA study is meant to assess whether taking BIIB122 orally once a day can slow clinical worsening compared with placebo in Parkinson's disease patients who don't have a pathogenic LRRK2 variant. We also expect to launch the Phase III LIGHTHOUSE study before this year ends, which is designed to assess how safe and effective BIIB122 is in Parkinson's disease patients whose LRRK2 pathogenic variant has been confirmed. Around 10 million people globally live with Parkinson's disease, and there aren't any approved treatments that slow disease progression. By blocking LRRK2, we could potentially bring forward a first-in-class therapy capable of meaningfully changing the course of the disease. To wrap up, we delivered well on our R&D objectives during the second quarter and keep prioritizing our efforts across both therapeutic areas and programs. As Michel said, we've already made a number of decisions stemming from that prioritization effort, and the process continues, driven by scientific insights as well as internal inflection points. As we look at the rest of 2022, we expect several exciting milestones. Among them are the zuranolone regulatory filings for MDD and PPD in the U.S., the Phase III readout for lecanemab in Alzheimer's disease, and the start of mid- to late-stage studies in Alzheimer's, Parkinson's and lupus. These therapeutic areas have significant unmet need, and they're places where Biogen can potentially deliver first-in-class and best-in-class therapies to patients. I'll now hand the call over to Mike.

Mike McDonnell

executive
#4

Thanks, Priya, and good morning to all of you. I'll walk through a few key points on how we performed financially in the second quarter, and then I'll give an update on our guidance for the full year 2022. Just so everyone's clear, every financial comparison I make is against the second quarter of 2021, unless I say otherwise. Our total revenue came in at $2.6 billion for the second quarter, which works out to a drop of 7% at actual currency and 5% at constant currency. On a non-GAAP basis, diluted earnings per share for the second quarter landed at $5.25, which is down 6%. Total MS revenue, including OCREVUS royalties, reached $1.7 billion, a decline of 4% at actual currency and 3% at constant currency. Turning to TECFIDERA, global revenue was $398 million, down 18% at actual currency and 17% at constant currency. Sequentially, TECFIDERA revenue in the U.S. did go up compared with the prior quarter. That said, the increase largely reflected channel dynamics, and we do anticipate that TECFIDERA in the U.S. will decline for the rest of 2022. In markets outside the U.S., generic competition had a modest effect on TECFIDERA in places like Canada and Germany. As things stand, we know of a number of generic applications that have received approval in Europe, and we'll be watching that situation carefully. On an important note, we were glad to secure a new patent in the EU, and we retain all rights to enforce that patent against generics that infringe, though generics could still choose to launch at risk. For VUMERITY, global revenue was $137 million, an increase of 51% at actual currency and 52% at constant currency. VUMERITY kept growing in the U.S. We're happy with how it's tracking. Beyond the U.S., VUMERITY has now launched in 14 markets. Right now we're coordinating with our contract manufacturing suppliers to resolve possible supply constraints, and because of that we've pushed back any further country launches. Global TYSABRI revenue was $516 million, a decrease of 2% at actual currency and flat at constant currency. Within the United States, TYSABRI revenue took a hit from modest volume declines, which favorable pricing partly offset. Outside the U.S., we were glad to see patients continuing to grow. We're aware that regulatory filings for a biosimilar referencing TYSABRI have gone in to both the FDA and the EMA. We'll keep enforcing our IP, but a biosimilar could launch once approved in the U.S. and EU, and that could happen next year. Global Interferon revenue was $350 million, a decrease of 13% at actual currency and 11% at constant currency, and it was affected by the ongoing shift away from the injectable platforms toward oral or high-efficacy therapies. Compared with the prior quarter, Interferon revenue rose 13% at actual currency and 14% at constant currency, mainly because of seasonality and channel dynamics in the U.S. Now on to SMA. Global SPINRAZA revenue was $431 million, a decline of 14% at actual currency and 11% at constant currency. In the U.S., it was encouraging to see fewer SPINRAZA discontinuations over the quarter. Outside the U.S., the drop in revenue was mostly the result of competition, together with the timing of shipments in certain markets, pricing dynamics and negative currency impacts. Worldwide SPINRAZA sales came in 9% lower than Q1 2022 on a reported basis, and 8% lower excluding currency effects, with competition, unfavorable foreign exchange outside America, and certain seasonal patterns in the U.S. all playing a role. Turning to biosimilars. That business brought in $194 million, down 4% as reported but up 3% in constant currency. Greater volumes for biosimilars were outweighed by currency headwinds and price erosion. Our outlook remains that biosimilars revenue for the entire year will come in below 2021. We were glad to bring BYOOVIZ to the U.S. market during the quarter, booking a small amount of early revenue from channel stocking. Keep in mind that BYOOVIZ will roll out gradually, contributing more substantially beginning in 2023. Anti-CD20 revenue overall reached $436 million, a 1% decrease. OCREVUS royalties rose 14%, though that gain was outweighed by ongoing RITUXAN erosion from biosimilar competition. Shifting now to costs and the balance sheet. Non-GAAP R&D spending for Q2 was $529 million, which included $18 million of upfront payments tied to our collaborations with MedRhythms and Alectos Therapeutics. That compares with $585 million in Q2 2021, a figure that contained roughly $50 million of upfront payments. Non-GAAP SG&A came to $570 million, of which about $29 million was tied to ADUHELM. The year-ago quarter's figure was $635 million. Collaboration profit sharing in Q2 was a net expense of $29 million, reflecting $58 million of net profit sharing expense from the Samsung Bioepis collaboration, partly offset by $29 million reimbursed by Eisai for ADUHELM's U.S. commercialization. Non-GAAP other expense totaled $79 million, largely from interest expense. GAAP other income was $429 million, and it contained two notable items. First, we booked a gain of roughly $1.5 billion on selling our equity stake in the Samsung Bioepis joint venture. Second, we recorded $900 million plus estimated fees and expenses tied to an agreement in principle resolving previously disclosed qui tam litigation concerning conduct before 2015. This agreement in principle carries no admission of liability and depends on final settlement agreements and documents being negotiated. We anticipate making the payment soon after those agreements are finalized, which we hope will be as quickly as possible and no later than 12 months from now. Cash flow from operations during the second quarter was $737 million. Capital expenditures totaled $37 million, leaving free cash flow of $700 million. We bought back 2.4 million shares of common stock in the quarter, spending $500 million. At June 30, the quarter closed with $7.3 billion of debt, $5.9 billion in cash and marketable securities, and $1.4 billion of net debt; during July, we paid off our senior notes maturing September 2022, which had an aggregate principal amount of $1 billion. Also worth noting: as of June 30, we have capitalized about $71 million of work-in-process inventory tied to lecanemab. Our intention is to keep growing inventory during the months ahead, and we're additionally securing the raw materials tied to that manufacturing. Should the lecanemab Phase III trial fail, or should lecanemab not be granted regulatory approval, then we would anticipate charging inventory then on hand to research and development expense, subject to cost sharing with Eisai. On the whole, our financial standing remains very strong, with considerable cash and financial capacity, among which is a $1 billion undrawn revolving credit facility, to put money into expanding the business over the long term. Now let me move to our revised full year 2022 guidance; we are lifting our full year revenue guidance from the earlier range of $9.7 billion to $10 billion up to a new range of $9.9 billion to $10.1 billion, and lifting our full year non-GAAP diluted EPS guidance from the earlier range of $14.25 to $16 up to a new range of $15.25 to $16.75. This bump to guidance stems mainly from top line performance that came in better than expected along with ongoing cost management. The guidance presumes that foreign exchange rates as of July 15 will stay in effect through the rest of the year, net of hedging activities. Significantly, we are raising both our revenue and EPS guidance ranges in spite of some sizable currency headwinds, which were absent from our guidance when the year began. To be specific, after we issued our most recent guidance on May 3, we have absorbed a headwind of roughly $55 million to revenue and $0.20 to EPS from currency movements between April 29 and July 15; that comes on top of a headwind of roughly $120 million to revenue and $0.35 to EPS from currency movements between January 1 and April 29. These currency headwinds arise chiefly because the U.S. dollar has strengthened against other currencies in which we transact. This financial guidance presumes RITUXAN revenue keeps declining because of biosimilar competition, as well as continued erosion of TECFIDERA revenue in the U.S. because of generic entry. In addition, this guidance reflects a range of scenarios for how TECFIDERA generics will affect the EU, which is hard to forecast. We know of a small number of generics that have launched so far, and we are watching the situation; we assume we will use a portion of the remaining share repurchase authorization of $2.3 billion across the rest of the year. For other important guidance assumptions, please see our press release. To sum up, we kept executing well throughout our core business and are glad to be raising our financial guidance for the year. We stay focused on delivering results and are optimistic about the potential opportunities ahead that we believe can create long-term value for shareholders. We will now open the call for questions. Global interferon revenue of $150 million decreased 13% at actual currency and 11% at constant currency.

Brian Abrahams

analyst
#5

Nice quarter — congratulations. We picked up on something, and you touched on it somewhat: you've been halting pipeline programs at an earlier stage, 104, 100, and 076 among them. Could you perhaps speak to whether that says anything about a shift in how you think about taking on risk and making go/no-go calls when prioritizing the pipeline? And possibly how — whether that might signal anything about the bar you'd set for seeking approval of lecanemab should the Phase III study fail to hit its primary endpoint.

Michel Vounatsos

executive
#6

Priya will give some color.

Priya Singhal

executive
#7

Brian, thanks for asking that. As we said during the prior quarter, we've started a highly targeted, disciplined effort to prioritize our R&D portfolio. That said, it hinges on both internal inflection points and scientific insights coming from outside. Let me focus specifically on the points you raised regarding BIIB104. We've just announced that development of BIIB104 — an AMPA potentiator for CIAS, meaning cognitive impairment associated with schizophrenia — is being discontinued. The reason is that TALLY gave us a readout showing the pharmacological exposure we anticipated, yet neither the primary nor the secondary endpoints were met. Our view is that the hypothesis has now been tested quite thoroughly, so it's time to revisit the data, examine it closely, consider other possible applications, and make sure resources go toward programs with a greater chance of success. That covers that question. Turning to BIIB076, which you also brought up: it's an anti-tau antibody developed through our partnership with Neurimmune. We did announce that Biogen is halting development of it. Any additional questions about what comes next for BIIB076 should go to Neurimmune. From where we sit, our focus is on things like BIIB080, our antisense oligonucleotide targeting all post-translational forms of tau, and later this year we'll launch a Phase II trial — a late-stage, mid-stage study. That's the lens through which we approach prioritization. Last, on what this does to our bar in Alzheimer's, I'll simply note that we're eager to see results from Clarity AD for lecanemab; that trial is well-powered and well-designed. In our view, it carries the correct primary endpoint in CDR-Sum of Boxes. A statistically significant difference compared with placebo would, we believe, be clinically meaningful, given the instrument used as the primary endpoint along with all the secondary endpoints. Beyond that, we have an entire comprehensive program for lecanemab covering presymptomatic patients, plus work on maintenance with Eisai, a Phase II open-label extension, and subcutaneous administration. So I think we simply wait for the data. As stated previously, assuming Clarity AD is positive, we anticipate finishing the filing by Q1 2023. Hopefully that answers your question.

Michel Vounatsos

executive
#8

Also, if I could jump in, we're very happy that we're moving ahead with submitting zuranolone and leca, and we're also awaiting additional data for adu. When it comes to the earlier-stage pipeline, we've grown it quite a bit; it makes sense that, to begin with, neuroscience carries built-in risk, and it makes sense that we're always aiming to boost the likelihood of success and to pick things according to trigger point and the science within. That's exactly what Priya is doing.

Matthew Harrison

analyst
#9

Thanks. I was hoping to get more detail about lecanemab. The main thing people keep asking me is whether, when you talk with the FDA about relying on one confirmatory trial, you've received clear guidance from the agency regarding what p-value would be required. Or will that instead be something decided during review?

Michel Vounatsos

executive
#10

Priya?

Priya Singhal

executive
#11

Appreciate that, Matthew. Let me give a bit of context here. Lecanemab has finished — actually, it's already submitted under the accelerated approval route, based on the Phase II trial, the 201 study — and we're waiting on data from Clarity AD, the Phase III trial. That trial enrolled 1,795 participants. It's conducted globally. Our view is that it has solid statistical power. No interim look or futility assessment is planned. The readout will simply be the primary analysis, expected at some point during the fall of 2022. Also, as things stand, this study includes an underrepresented population, fairly comparable to the CMS population, with roughly 25% represented. As for whether it could serve as a confirmatory trial supporting traditional approval — yes. Our belief is that we have an agreement in place that if the results come out positive, it can act as the confirmatory study; so yes, that is precisely our position; beyond that, let me also point out that in the aducanumab briefing document, the FDA indicated it would accept a statistically significant change on an inherently meaningful instrument, for example the CDR-Sum of Boxes, as proof of a clinically meaningful effect; that point matters a great deal. And we're fairly confident that CDR-Sum of Boxes is the correct primary endpoint. It has clinical validation, it captures both cognition and function, and it's broadly recognized as a registrational endpoint. So that's where we stand. We're feeling quite positive about the fact that the study has solid power. Naturally, we must wait for the data. I hope that addresses your question.

Colin Bristow

analyst
#12

Nice work on the quarter. Turning to the CEO search, can you tell us how things stand right now? And if possible, share a timeline. Also, within that same question, since lecanemab matters so much to the company and its trajectory, would it be fair to think a new CEO might not be appointed until after we know the trial's outcome?

Michel Vounatsos

executive
#13

Thanks for asking. Based on what I heard earlier this week when I spoke with Board members and our Chairman, the search is moving along as expected. Still, at this point, there's nothing to share yet. And clearly, we won't speculate on lecanemab, though it's a very important event; but right now, nothing further to report.

Michael Yee

analyst
#14

My question concerned spending on SG&A—how it plays out for lecanemab—and whether a choice point exists regarding your obligation to cover 50 to 50, plus how that functions if the drug reaches the market; second, regarding zuranolone, the same issue. Is that a planned net investment outlay for 2023? What's our framework for that?

Mike McDonnell

executive
#15

Right. Those two agreements are each structured 50 to 50. Consequently, you'd anticipate that we'll definitely be developing infrastructure to enable, ideally, a successful launch for each product, and in both situations we split expenses evenly, 50 to 50. Thus, we're intensely focused on controlling our OpEx. Right now, 2022 guidance points to a midpoint near $4.6 billion compared with $5.2 billion in the prior year, and we're making solid progress on the cost actions we've pledged to take. Beyond that, naturally, the commercial build-out for those two products represents crucial priorities that we're addressing in close coordination with both Sage and Eisai, especially when it comes to preparing for 2023 and afterward.

Umer Raffat

analyst
#16

If the primary endpoint fails, but a secondary measure such as ADCOMS or ADAS-Cog, or maybe a subgroup such as APOE4 carriers, shows activity, how do you plan to handle the lecanemab Phase III data set? And what effect would that have on your submission to the FDA?

Priya Singhal

executive
#17

Thanks, Umer. Perhaps I should take a step back and note that when it comes to how the data read out, there are clearly multiple possibilities. At one extreme, we could see a positive result on the primary endpoint along with the secondary endpoints. In our view, the data in their entirety will matter a great deal. As I mentioned before, we have talked this through, and the FDA has agreed with us that a positive readout might be usable as a confirmatory study. At the opposite extreme, the study might turn out negative. In that case, we would also examine the other readouts, since there are two — these are, of course, the Biogen-Eisai readout, but I would also point out that two additional anti-amyloid agents will report out soon. As everybody is aware, one is gantenerumab, and the other is donanemab. So the larger issue here really concerns these readouts and their implications for the anti-amyloid hypothesis in Alzheimer's — early Alzheimer's disease. There may be a number of mixed scenarios, including some that you described, and pinning down precisely how those would be viewed, I think, would be very hard. So regarding the mixed scenario, there could be many different permutation combinations, yet the data in their entirety, I believe, will be what matters; therefore, at this stage, it would be difficult for me to guess which mixed scenario might arise and what result it might produce. Still, we are taking all of this into account; and at present, I would say our attention is on making sure we gather the data, finish the study, obtain a very clear readout, and after that we will, naturally, be in discussions with the FDA. That is because this product also holds breakthrough and Fast Track designation, which lets us seek the FDA's guidance; so we will stay in close touch, and that is all I can share. Thank you.

Marc Goodman

analyst
#18

You continue to bring up the expansion potential in emerging markets. Could you assist us in gauging the scale of this business? What has its growth trajectory looked like? Which main products are driving growth in those regions? Which offerings haven't been introduced there yet that are in development and might fuel future growth? Just provide us with an idea of where this business will stand in 3, 4 years.

Michel Vounatsos

executive
#19

So prior to Mike giving — offering additional detail, the crucial factor is that the disease patterns are quite comparable in this, in the West, in emerging mature markets; thus our product lineup is highly applicable to this region. The second thing is that we observe a very robustly rising middle class that can afford, can co-pay and is eager to obtain top education and health care. And what we've experienced thus far with our broadened presence over several years in Latin America, in Asia Pac, in the Middle East, is that we witness a very favorable adoption of our MS portfolio even though we initially believed that in Asia Pac, it was somewhat lower incident. But given the size of the population, these are very viable opportunities; we observe a very favorable adoption and also for SPINRAZA. So a solid opportunity. We possess a professional team. Compliance matters greatly everywhere, but also in this region; so we ensure that we maintain a very solid equilibrium between where Biogen operates directly and where Biogen works with partners, but we have delivered very solid results so far with a robust double-digit momentum. Mike?

Mike McDonnell

executive
#20

Right, Marc, there isn't much more for me to share. What I'd highlight is that two markets in particular have us feeling good — China and Brazil. With China specifically, the response to SPINRAZA has been very strong. Because of how pricing works in that market, it isn't bringing in a large amount of revenue. Still, on the whole, most of the growth we've seen internationally has come from SMA. That said, as Michel mentioned, MS also presents an opportunity. It has moved from generating very little revenue to a solid figure here in 2022, and it's expanding as we look further out. So our hope is that we can keep growing it in a meaningful way over the coming several years.

Salveen Richter

analyst
#21

Could you give us any updates on your thinking around zuranolone's pricing and branding, plus your views on how a possible Schedule IV might affect utilization?

Michel Vounatsos

executive
#22

Well, to begin, the data has us feeling very encouraged. It's great to see the second study, in postpartum, for the study in major depressive disorders. We've had chances to meet with a great many constituency. This disease touches so many people, which makes it so pertinent. Unless I'm wrong, here in the U.S., over 19 million, as Priya mentioned, with an incidence for PPD near 0.5 million annually; so it's extremely pertinent. We're advancing considerably on positioning, on grasping the patient journey, and on the various market segments, from the naive to those failing treatment in the manner we recognize in this enormous market because of side effects or insufficient efficacy. My hope is that soon we'll be — we'll get a chance, alongside Sage, to hold a dedicated session with you to bring you up to date on where things stand, and we'll return to this at the earliest opportunity. As for price, we aren't there yet. We're doing some of our homework, but there's nothing to add at this point.

Priya Singhal

executive
#23

Sure, I can take that scheduling question. Thanks, Salveen. What I'd like to point out is that, looking at the bigger picture, the DEA's process is really quite thorough, and normally toward the end of the approval timeline — roughly a 3-month period — they'll assign a schedule. As I noted in my opening remarks, Sage has by now finished its human abuse liability potential study. There are potentially 5 different schedules you might be given. Right now, all we have to go on is our own data, plus what we know from the background of ZULRESSO, a Schedule IV drug. Given that, we currently think zuranolone could land in Schedule IV. What Schedule IV generally signifies is a low potential for abuse together with low risk for dependence. Ativan, Xanax, and Darvocet are among the other drugs falling into this category. Our present expectation is that this will be the scheduling we receive. Naturally, we won't know the actual outcome until the process plays out, but based on the data in hand, that's what we anticipate right now. I hope that answers it. Thank you.

Robyn Karnauskas

analyst
#24

Apologies, my voice is going. You've discussed at length remaining inside the existing neurology pillars, and perhaps immunology too. My question is: when you consider reducing portfolio risk and possibly moving beyond those pillars, where do your thoughts stand right now, given you've had a quarter to consider it? And related to that, I suppose, would that call be made once the permanent Head of R&D and CEO are in place?

Priya Singhal

executive
#25

Let me begin. Thanks for asking. To take a step back, here at Biogen, we hold a vision of a portfolio spanning multiple franchises. And our R&D pipeline, I'd say, is pretty strong, diversified, and robust. In the clinic we have 29 programs, with many additional ones in discovery and exploratory work, where we examine the diseases we aim to lead in and consider the targets and biological pathways we might tackle using our platform across multiple modalities. That's another advantage we hold. We can remain agnostic on modality, since we can access biologics, small molecules, antisense oligonucleotides, and gene therapy too. So that's roughly the big picture. That's our approach to the R&D portfolio; within it, you mentioned neuroscience; that's an absolute core strength for us. It's an extremely difficult area, I'd admit. I think all of us would admit that. Yet we've achieved considerable success there, in multiple sclerosis and in spinal muscular atrophy. And we might achieve success in Alzheimer's; and of course, we have zuranolone in depression. So we view this as neuroscience, possibly deepening our emphasis on neuropsychiatry, where we now have a product under filing for both MDD and PPD, with substantial high unmet need, and we're exploring other possible indications for the GABAA pathway that zuranolone targets. So zuranolone might truly amount to far more than just MDD and PPD, and we're examining that too within our portfolio prioritization. Turning to specialized immunology. We have three Phase III trials, and this matters greatly, involving two products; so we have our in-house BIIB059, where our grasp of the biology and the pathway is very solid. We believe it might be first-in-class, best-in-class for CLE, cutaneous lupus erythematosus, and also for SLE. And then there's dapi through our collaboration with UCB, also in Phase III; so this is a comprehensive portfolio in SLE and CLE alone. There again, we're considering where else we understand the type 1 interferon signature, where else BIIB059 might yield potential indications, for instance, in other specialized immunology indications? That's our core focus at present. And lastly, regarding neuroscience, our belief is that we can lead in Alzheimer's and depression while keeping our top position in MS and SPINRAZA. On SMA, we've already publicly shared our decision to opt in for BIIB115, an ASO follow-on that might allow dosing just once per year. That could truly matter a great deal. We're pushing that forward as fast as possible. Then in MS, we keep considering BTK inhibitors; we have one that acts peripherally. There's also a central BTK inhibitor, and we'll keep reviewing new data as it comes and then decide. Past this main R&D portfolio, as Michel noted, biosimilars and digital therapeutics are also ours. With MedRhythms, we've recently taken a first step. My view is that taken together, this makes for a highly varied portfolio. One place where our attention has grown sharply is that whenever we get something like the BIIB104 readout, we start asking what else could be done involving that glutamatergic pathway and whatever data we collect from it. In the same way, with BIIB059 and zuranolone, as I said, how should resources be assigned? What should come first? So we're handling this in a highly methodical way, and it's a challenge to R&D and the whole One Biogen team to carry this out really well. Hopefully that gives you a sense of our approach.

Michel Vounatsos

executive
#26

Thank you, Priya. To pull this all together, getting a clear picture of the main strengths we hold across the company — spanning the entire value chain, from initial research and clinical development through to commercialization and how we engage customers — matters a great deal when it comes to setting where we're headed strategically. And, as Priya mentioned, we now see ourselves as considerably more diversified than was the case 6 years back, across neuroscience, specialized immuno, biosimilars, and the emerging capability in digital therapeutics; at this point we have 29 programs, 10 of which are in Phase III or are filed products. The real question becomes: how do we further reduce risk? That's precisely what Priya has begun focusing on. Naturally, with a new CEO and a permanent Head of R&D, there will be a chance to take another look at the strategy alongside the Board.

Cory Kasimov

analyst
#27

Let's return to Alzheimer's briefly. Given the latest NCD, and with the CLARITY study clearly still awaiting results, how do you weigh how much the January PDUFA for lecanemab matters for accelerated approval, which rests mainly on Phase II data? Also, has the FDA signaled whether an ADCOM will be held for that first application?

Michel Vounatsos

executive
#28

Priya?

Priya Singhal

executive
#29

Thanks, Cory. To begin with, I want to take a step back and note that we submitted under the accelerated approval route using the Phase II data, which you brought up, Cory, and the PDUFA date is January 6, 2023. Clarity AD is going to report in the fall of this year, though. If the results turn out positive, then the submission seeking traditional approval will be finished by the end of the first quarter of 2023, per what Eisai has communicated. Beyond that, I believe the full picture of the information and the data is what will determine the outcome. Right now, we have — there's no sign that an advisory committee will be convened. As things stand, we don't have that sign. So that's everything I can share with you on — regarding that. Hopefully I've covered all parts of your question.

Jay Olson

analyst
#30

Could you explain the reasons BIIB104 failed to hit either the primary or the secondary endpoints in the Phase II TALLY study? Also, might you pursue BIIB104 in studies for other indications?

Priya Singhal

executive
#31

Thanks, Jay. That's an excellent question. Yes, the negative result for BIIB104 leaves us quite disappointed. To take a step back, the idea we set out to test was whether boosting AMPA activity could counter NMDA hypofunction — hypofunction of the NMDA receptor — and in that way boost synaptic connectivity and enhance the working memory domain — have a positive effect on working memory in the cognitive impairment tied to schizophrenia. That was the idea. We had been eager to see how it turned out. Naturally, it failed to achieve the primary and secondary endpoints; in neuropsychiatry studies, adherence and compliance during the study can sometimes fall short. So we examined PK exposures and related measures very closely. This readout covered 12 weeks. So we did that review, and we are fairly — we feel fairly sure this study had very high compliance, with exposures for BIIB104 matching what we expected across the full 12-week period. Thus, we think we put the idea of AMPA potentiation producing NMDA potentiation to the test as well. That said, we regard this as an exceptionally well-executed study, and the rich data set we gathered can point us toward ways to go after the glutamatergic pathway in other neuropsychiatry indications. So yes, that's something we are examining closely, and we will assess it closely; we had earlier Phase I studies, but sadly that data did not replicate. These were quite small studies, though. One enrolled healthy volunteers, while the other involved schizophrenia patients, yet both ran for a shorter time, and the participant counts came to 39 and 29, respectively. So quite small studies; so yes, in response to your question, neuropsychiatry stays a major area of emphasis. We think we have strengthened our capabilities and attention here, and we'll keep reviewing this top-quality data set, and we will also share it at future medical meetings.

Phil Nadeau

analyst
#32

This is a follow-up to what Cory asked, but it's aimed squarely at Mike. Mike, what's Biogen's stance on committing resources to the lecanemab launch? When would the infrastructure get built, and when would the product truly launch? Would that come following accelerated approval, or after full approval? Or does it look like there's yet another step inside NCD that's probably going to arrive at some point? So at what moment would Biogen be comfortable actually putting money into the commercial infrastructure for this program?

Michel Vounatsos

executive
#33

Before Mike responds, let me say that we collaborate fully and closely with our Eisai partners, that what we're approaching is a launch on a global scale, not one that suddenly happens just in the U.S., and we expect the filing in Japan and with EMA to occur in the first half of 2023. So a global launch is what this will be. And clearly, as everyone knows, a sequential process exists here, going from an accelerated approval to a possible full approval afterward. Mike?

Mike McDonnell

executive
#34

Yeah. I believe Michel addressed quite a bit of that when answering your question, Phil, yet let me add a reminder: for lecanemab, both our company and Eisai anticipate the Phase III data readout during fall 2022. The PDUFA date falls in early January of '23. As you're aware, in its present form, the national coverage determination meaningfully restricts the market opportunity for antibodies granted accelerated approval; therefore, as Michel noted, we'll work in close coordination with Eisai to allocate resources suitably; we'll absorb whatever lessons ADUHELM offers where applicable, and at every stage of commercialization we'll ramp up resourcing quite gradually as lecanemab gets launched. Naturally, I'd note, we did choose to dismantle the ADUHELM commercial infrastructure since we judged the time gap too wide relative to when lecanemab would require it. And in my view, that call was correct. We believe we can rebuild that infrastructure more incrementally and rather swiftly once we're ready; and once more, that's something we'll do in very close partnership with Eisai.

Michel Vounatsos

executive
#35

My view is that this really hinges on how good the data turns out to be. Should the data make things clear and confirm, with no ambiguity at all, that clearing out the plaque is linked to a slowing of cognitive decline, and if it backs up the hypothesis, then I'd say things move ahead more quickly than our current expectations suggest.

Mike McDonnell

executive
#36

Right, and one more point to keep in mind — this is strictly an accounting matter, and it connects somewhat to what Mike Yee brought up before. Just to reiterate, every bit of the revenue and costs gets combined, and our 50% portion shows up as a single-line revenue item for lecanemab.

Geoff Meacham

analyst
#37

I'd like to build on a few earlier inquiries regarding lecanemab. You've already addressed the opportunity here in the U.S., but what level of dialogue have you had with regulators in the EU or Japan concerning the risk/benefit threshold? I was uncertain whether your earlier conversations from adu might have offered some clarity on that front.

Priya Singhal

executive
#38

Thanks, Geoff; Eisai has stated that they intend to finish filings in Europe and Japan by the close of Q1 2023, which mirrors the U.S. schedule closely; naturally, this assumes the Clarity AD readout comes back positive. Consistent with that message, every interaction with regulators globally is aligned — consultation has been ongoing. When it comes to Japan, Eisai has said, and we've said before, that they took part in its prior consultation process. That prior consultation pathway in Japan can genuinely speed up the review, provided the data turns out positive; so that is underway as well. So everything remains on schedule for completing the submission. Benefit/risk will always shape these talks, and we feel the trial has been built, sufficiently powered and properly designed, to deliver an answer using a clinically validated instrument. So our view is that it's well set up. Of course — what happens beyond that hinges on the data.

Evan Seigerman

analyst
#39

When we consider the Clarity AD trial down the road, what does CMS, in your view, have to observe from it before they might change the NCD? There's clearly plenty of talk about this on today's call. Still, I want to know whether that would be enough to basically unlock coverage for people on Medicare.

Priya Singhal

executive
#40

Thanks, Evan. Before I get right to that, I believe we ought to restate something important: according to the finalized NCD, antibodies granted full approval are permitted to be covered through prospective comparative studies that CMS has approved — though such data might be gathered via a registry. What remains ambiguous is the subsequent point they raised: how stringent these study designs must be could hinge considerably upon how strong the evidence was in the original randomized controlled trial behind the FDA's approval. On that front, our confidence is fairly high, since we regard the trial as soundly designed, properly constructed, and adequately powered for a clear readout. Thus, should that trial — meaning Clarity AD — produce positive results, we think there's a possibility it would clear the rigorous evidence threshold articulated by CMS in the NCD, and they might revisit the question of granting full coverage. Another thing worth weighing: two additional readouts are arriving around the same period, and those might shape how CMS views its own guidance and what it labels as a high level of evidence. So right now, we can't say with certainty; it will come down to each molecule — in my own view, that means Phase III data. As Eisai has stated publicly, Clarity's design is a strong one, and in their assessment it could satisfy the high evidence standard laid out by CMS within the NCD memo. We therefore do believe reconsideration is possible; and in my view, high-level evidence would need to encompass safety, efficacy, and underrepresented populations that reflect the CMS population. Beyond that, I'd note the Clarity AD population includes comorbidities and concomitant medications that aren't so different from those of the CMS population, so these factors position us favorably and look encouraging. The ultimate result, though, will rest on what the data show.

Michel Vounatsos

executive
#41

Also, building on Priya's remarks, in addition to the strong design, an open-label extension is going to contribute further data. A preclinical study is additionally underway for the earlier population, and there are life cycle management possibilities, with a new subcutaneous formulation likewise in development.

Mike Hencke

executive
#42

And that will conclude our call today. Thank you, everyone, for joining us.

Operator

operator
#43

That will conclude today's call. We appreciate your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.